Inhibiting cancer cell hallmark features through nuclear export inhibition  

作　　者：Qingxiang Sun Xueqin Chen Qiao Zhou Ezra Burstein Shengyong Yang Da Jia 

机构地区：[1]State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy,Sichuan University,Chengdu,China [2]Department of Pathology,West China Hospital,Sichuan University,Chengdu,China [3]Department of Internal Medicine,UT Southwestern Medical Center,Dallas,Texas,USA [4]Department of Molecular Biology,UT Southwestern Medical Center,Dallas,Texas,USA [5]West China 2nd University Hospital,Sichuan University,Chengdu,China

出　　处：《Signal Transduction and Targeted Therapy》2016年第1期91-100,共10页信号转导与靶向治疗（英文）

基　　金：QS is supported by National Natural Science Foundation of China(NSFC),fund number 80502629;EB is supported by NIH R01-DK073639 and CPRIT grants;DJ is a‘Junior One Thousand Talents’program scholar.

摘　　要：Treating cancer through inhibition of nuclear export is one of the best examples of basic research translation into clinical application.Nuclear export factor chromosomal region maintenance 1(CRM1;Xpo1 and exportin-1)controls cellular localization and function of numerous proteins that are critical for the development of many cancer hallmarks.The diverse actions of CRM1 are likely to explain the broad ranging anti-cancer potency of CRM1 inhibitors observed in pre-clinical studies and/or clinical trials(phase I–III)on both advanced-stage solid and hematological tumors.In this review,we compare and contrast the mechanisms of action of different CRM1 inhibitors,and discuss the potential benefit of unexplored non-covalent CRM1 inhibitors.This emerging field has uncovered that nuclear export inhibition is well poised as an attractive target towards low-toxicity broad-spectrum potent anti-cancer therapy.

关 键 词：ATTRACTIVE LIKELY BENEFIT 

分 类 号：F75[经济管理—国际贸易]